Big Board

Content Ideas
Result Content Idea Research
Result Content Idea Research
1 End of Year, Change of Careers
2 Tecentriq-Avastin Combo Approved in Europe for Advanced or...
3 FDA Approves Merck's Keytruda, Agilent CDx in PD-L1-High Triple-Negative Breast Cancer
4 FDA Approves Genentech's Tecentriq as a First-Line Monotherapy for Certain People With Metastatic Non-Small Cell Lung Cancer
5 Renal Cancer Study Finds Disease Subsets Determine Response to Angiogenesis Blockade Therapy
6 Genentech's Tecentriq Comes Up Short in Phase III Breast Cancer Study
7 Atezolizumab/Bevacizumab Approved in Europe for Advanced or Unresectable HCC
8 Chinese biotech Zai Lab nabs Roche cancer veteran as new R&D exec, drug hunter
9 Long HCC pipeline marks change for previously stagnant market, says an
10 Another FDA approval for Genentech's Tecentriq
11 Genentech's Tecentriq in Combination With Chemotherapy (including Abraxane) Meets Primary Endpoint of Improved Pathological Complete Response, Regardless of PD-L1 Status, as Initial Treatment for People With Early Triple-negative Breast Cancer
12 Genentech's Tecentriq, Paclitaxel Combo Fails to Improve PFS in PD-L1-Positive TNBC
13 Genentech's Tecentriq-Avastin Combo Fails to Hit Primary Endpoint in Ovarian Cancer
14 FDA Approves Genentech's Tecentriq plus Cotellic and Zelboraf for People With Advanced Melanoma
15 Cancer Patients With BRCA1/2 Mutations Respond Differently to Immunotherapy, Study Shows
16 FDA Approves Genentech's Tecentriq in Combination With Avastin for People With the Most Common Form of Liver Cancer
17 Long HCC pipeline marks change for a previously stagnant market
18 FDA Grants Priority Review to Genentech's Tecentriq Monotherapy as First-line Treatment of Certain People With Advanced Non-small Cell Lung Cancer
19 Genentech's Tecentriq Misses Mark in Urothelial Cancer Trial
20 FDA grants priority review to Genentech's Tecentriq as first-line treatment of certain people with advanced NSCLC
21 Genentech Presents New Data From Multiple Phase III Studies of Tecentriq in Triple-Negative Breast Cancer at ESMO Virtual Congress 2020
22 ESMO: Genentech Shares Data from Phase III Triple-Negative Breast Cancer Trials
23 FDA Approves Genentech's Tecentriq Plus Chemotherapy (Abraxane and Carboplatin) for the Initial Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
24 Merck's Keytruda nets another approval, this time in triple negative breast cancer. Can it catch up to Tecentriq?
25 Genentech's Tecentriq (Atezolizumab) Improves Overall Survival as a First-line Monotherapy in Certain People With Advanced Non-small Cell Lung Cancer
26 Genentech's Double Checkpoint Inhibitor Combo Shows Promise in Lung Cancer
27 Exploratory Study Finds Genomic Markers of Response to Tecentriq, Avastin in Advanced Liver Cancer
28 Genentech's Tecentriq® (ATEZOLIZUMAB) Plus Platinum-based Chemotherapy Reduced the Risk of Disease Worsening or Death in People With Previously Untreated Advanced Bladder Cancer
29 Genentech Provides an Update on Phase III Study of Tecentriq in People With Muscle-invasive Urothelial Cancer
30 Genentech's Tecentriq-Avastin Combo Improves Survival in Liver Cancer
31 Genentech's Tecentriq in Combination With Avastin Increased Overall Survival and Progression-free Survival in People With Unresectable Hepatocellular Carcinoma
32 FDA Approves Atezolizumab/Bevacizumab Combination for HCC
33 Genentech's Tecentriq (Atezolizumab) as a First-Line Monotherapy Helped Certain People With Advanced Non-Small Cell Lung Cancer Live Longer Compared With Chemotherapy
34 Genentech Earns Another Lung Cancer Approval for Tecentriq
35 Infinity Pharmaceuticals Announces Presentations at the 2020 San Antonio Breast Cancer Symposium
36 Immune Checkpoint Inhibitors Market to Inspire a Growth up to US$ 40,882.6 Million by 2026 – Coherent Market Insights
37 New Data at the ASCO20 Virtual Scientific Program Reflects Genentech's Commitment to Accelerating Progress in Cancer Care
38 FDA Alerts Docs, Patients to Lack of Benefit With Tecentriq-Paclitaxel in Metastatic TNBC
39 Tag: Global Tecentriq Market
40 Genentech Scores FDA Approval for Tecentriq and Avastin Combo in NSCLC
41 FDA issues alert about use of Tecentriq with paclitaxel for breast cancer
42 Atezolizumab plus bevacizumab improves survival outcomes vs. sorafenib in unresectable HCC
43 Roche's Tecentriq combo approved in China for liver cancer
44 Tag: Tecentriq Market with COVID-19 impact analysis
45 FDA Grants New Indication for Tecentriq Plus Cotellic and Zelboraf for Advanced Melanoma
46 Tecentriq Market: Industry Perspective, Comprehensive Analysis, Size, Share, Gro
47 New Data from Ciforadenant Phase 1b/2 Clinical Study Presented at ESMO Virtual Congress 2020
48 Tecentriq misses mark in ovarian cancer trial
49 Tecentriq Plus Cotellic and Zelboraf Approved for Advanced Melanoma
50 Phase 3 trial of atezolizumab for urothelial cancer misses primary endpoint
51 FDA OKs Atezolizumab Plus Bevacizumab for Frontline Treatment of Advanced Liver Cancer
52 FDA Approves Tecentriq as Initial Treatment for Advanced NSCLC
53 Genentech Announces Phase III Study Results for Tecentriq Plus Cotellic and Zelboraf in People With Previously Untreated BRAF V600 Mutation-positive Advanced Melanoma
54 Atezolizumab combination extends PFS in BRAF V600-mutant advanced melanoma
55 FDA Approves 2 Therapies for Treatment of Metastatic Non–Small Cell Lung Cancer
56 FDA Approves Tecentriq-Avastin Combo for Newly Diagnosed Advanced...
57 Roche, BioNTech post 'low' response rate in cancer vaccine trial
58 FDA Warns Tecentriq-Paclitaxel Combination Failed to Treat Locally Advanced or Metastatic TNBC
59 ASCO Highlights: Takeda, Genentech, Johnson & Johnson and More
60 Genentech reveals updates from Phase 3 IMagyn050 clinical trial
61 Genentech Submits sBLA for Atezolizumab Plus Bevacizumab Combo to Treat Unresectable HCC
62 Atezolizumab regimen fails to extend PFS in triple-negative breast cancer subset
63 New Advancements Change HCC Treatment
64 Atezolizumab Leads to Longer OS for Some Types of Advanced NSCLC, Study Says
65 BioNTech's Personalized Cancer Vaccine, Tecentriq Yield Few Responses but Promising Immune Activity
66 FDA Grants New Breast Cancer Indication for Genentech's Tecentriq
67 FDA approves immunotherapy regimen for advanced liver cancer
68 Roche to present new data across 16 blood disorders at the American Society of Hematology 2020 Annual Meeting
69 Neoadjuvant atezolizumab, chemotherapy improve outcomes in triple-negative breast cancer
70 FDA Grants Priority Review to Genentech's Cancer Immunotherapy TECENTRIQ (Atezolizumab) for Initial Treatment of People With a Specific Type of Metastatic Lung Cancer
71 Genentech, Pfizer and Merck Identified as the Top Three Companies Driving Therapeutic Innovation in Breast Cancer
72 FDA Approves Frontline Atezolizumab Plus Carboplatin/Nab-Paclitaxel for Lung Cancer Subset
73 Litigation on Amgen's Biosimilar to Avastin Settles on Heels of Amgen Procedural Victory at Federal Circuit
74 Chugai wins additional HCC indication for Tecentriq and Avastin combo
75 VIDEO: Tiragolumab plus atezolizumab confers benefit for certain patients with NSCLC
76 Atezolizumab plus cobimetinib improves PFS in biliary tract cancer
77 Atezolizumab plus chemotherapy improves PFS in metastatic urothelial carcinoma
78 BRIEF—Chugai gets nod for new use of Tecentriq and Avastin
79 I-O blockbusters from Merck, BMS and more linked to poor COVID-19 outcomes: study
80 Drug Duo Is Promising in Older Patients With Advanced HCC
81 AACR Studies in BRAF-Mutated Melanoma Show Benefit of Combo Treatment, Continuous Dosing Strategies
82 AACR: Roche's triple threat—Tecentriq, Cotellic and Zelboraf—stalls melanoma progression
83 Phase III readouts spell disaster for Genentech's lead IBD drug
84 FDA approves four NSCLC regimens
85 FDA to Review Tecentriq-Avastin Combo for Newly Diagnosed Advanced...
86 Clinical Catch-Up: June 15-19
87 FDA grants priority review to cancer therapies
88 Singal and Kim Talk Trials and Treatments for HCC
89 Roche receives positive CHMP opinion for Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
90 Roche's Tecentriq and Companion Diagnostic Gets FDA Nod for Triple-Negative Breast Cancer
91 'Momentous' Data for First-Line Combo in Liver Cancer
92 Tecentriq (Atezolizumab)
93 New immunotherapies push SCLC market in USA over $1 billion, says anal
94 Immunotherapy Drug Boosts Survival for Lung Cancer Patients
95 Tecentriq-Avastin Combo for Liver Cancer Recommended for EU Approval
96 Infinity Pharmaceuticals Provides Company Update and Third Quarter 2020 Financial Results
97 Phase 3 IMpassion131 Study Fails to Improve Progression-Free Survival in Metastatic Triple-Negative Breast Cancer
98 Genentech, Blueprint Ink $1 Billion+ Deal to Develop Treatment for RET-Altered Cancer
99 Pharmacokinetic analysis of LADDER trial shows sustained efficacy of ranibizumab refillable implant
100 Tecentriq + Chemo Approved for First-Line NSCLC Without EGFR/ALK Mutations